KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CareDx (CDNA) Research & Development (2016 - 2025)

CareDx (CDNA) has disclosed Research & Development for 13 consecutive years, with $19.3 million as the latest value for Q4 2025.

  • Quarterly Research & Development rose 16.16% to $19.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $71.4 million through Dec 2025, down 1.49% year-over-year, with the annual reading at $71.4 million for FY2025, 1.49% down from the prior year.
  • Research & Development hit $19.3 million in Q4 2025 for CareDx, up from $16.8 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $24.4 million in Q1 2023 to a low of $16.0 million in Q1 2021.
  • Historically, Research & Development has averaged $19.7 million across 5 years, with a median of $19.2 million in 2021.
  • Biggest five-year swings in Research & Development: skyrocketed 65.45% in 2021 and later dropped 23.18% in 2024.
  • Year by year, Research & Development stood at $22.0 million in 2021, then grew by 6.91% to $23.6 million in 2022, then decreased by 20.11% to $18.8 million in 2023, then decreased by 11.74% to $16.6 million in 2024, then grew by 16.16% to $19.3 million in 2025.
  • Business Quant data shows Research & Development for CDNA at $19.3 million in Q4 2025, $16.8 million in Q3 2025, and $16.8 million in Q2 2025.